Antibody–drug conjugates (ADCs) are a promising cancer treatment modality that enables
the selective delivery of highly cytotoxic payloads to tumours. However, realizing the full …

Simple Summary Antibody-drug conjugates (ADC) are a rapidly expanding class of anti-
cancer drugs, with twelve agents in current clinical use. Despite recent successes, many …

Drug conjugates are conjugates comprising a tumor-homing carrier tethered to a cytotoxic
agent via a linker that are designed to deliver an ultra-toxic payload directly to the target …

Human epidermal growth factor receptor 2 (HER2) receptor tyrosine kinase is
overexpressed in 20–30% of breast cancers and is associated with poor prognosis and …

Antibody–drug conjugates (ADCs) combine cytotoxic payloads with monoclonal antibodies
through chemical linkers. Finding linkers that both enhance circulatory stability and enable …

Introduction In the field of bioconjugates, the focus on antibody–drug conjugates (ADCs)
with novel payloads beyond the traditional categories of potent cytotoxic agents is …

Ferritin–drug conjugates (FDCs) and antibody–drug conjugates (ADCs) respectively
represent the innovative and traditional mainstream approaches in drug delivery systems …

Monomethyl auristatin E (MMAE) is a potent tubulin inhibitor that is used as the payload for
four FDA-approved antibody–drug conjugates (ADC). Deconjugated MMAE readily diffuses …

Affibodies and designed ankyrin repeat proteins (DARPins) are synthetic proteins originally
derived from the Staphylococcus aureus virulence factor protein A and the human ankyrin …

This review summarizes recent development in synthetic drugs and biologics targeting
intracellular driver genes in epithelial cancers, focusing on KRAS, and provides a current …